Evidence map›Paper›PMID 21436585›Full record

ArticleThe Journal of clinical investigation2011

Nitrite-generated NO circumvents dysregulated arginine/NOS signaling to protect against intimal hyperplasia in Sprague-Dawley rats.

Matthew J Alef, Raghuveer Vallabhaneni, Evie Carchman, Sidney M Morris, Sruti Shiva, Yinna Wang, Eric E Kelley, Margaret M Tarpey, Mark T Gladwin, Edith Tzeng and 1 more

2 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 57 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01725256 phase2terminatednot on this mapstarted 2012, after this paper: background citation

A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension (PAH)

TypeinterventionalSponsorAires Pharmaceuticals, Inc.Ran2012 to 2014Enrolled29ConditionsPulmonary Arterial HypertensionArmsAIR001 (sodium nitrite inhalation solution)
NCT01725269 phase2terminatednot on this mapstarted 2013, after this paper: background citation

A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension

TypeinterventionalSponsorAires Pharmaceuticals, Inc.Ran2013 to 2014Enrolled17ConditionsPulmonary Arterial HypertensionArmsAIR001
3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Effect of pre-exercise dietary nitrate on skeletal muscle blood flow in a rat model of pulmonary hypertension.American journal of physiology. Regulatory, integrative and comparative physiology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Pro-Aging Effects of Xanthine Oxidoreductase Products.Antioxidants (Basel, Switzerland) · 2020
    Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Antiinflammatory actions of inorganic nitrate stabilize the atherosclerotic plaque.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Matthew J AlefDepartment of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Raghuveer Vallabhaneni
Evie Carchman
Sidney M Morris
Sruti Shiva
Yinna Wang
Eric E Kelley
Margaret M Tarpey
Mark T Gladwin
Edith Tzeng
Brian S Zuckerbraun
University of Pittsburgh · US

Funding

Storage Lesion in Banked Blood Due to Disruption of Nitric Oxide HomeostasisR01HL098032 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Mark T Gladwin · 2009 to 2026
$12.5M
Role of Arginase in Inflammation and TraumaR01GM057384 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MORRIS, SIDNEY MACHEN · 1998 to 2012
$3.8M
Myoglobin as a Nitrite Reductase that Regulates Hypoxic Cardiac NO SignalingR01HL096973 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GLADWIN, MARK T, SHIVA, SRUTI · 2010 to 2013
$1.5M
Dietary nitrate activation of PPARgamma improves insulin sensitivityRC1DK085852 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FREEMAN, BRUCE ALAN, GLADWIN, MARK T · 2009 to 2010
$999k
NHLBI NIH HHS R01 HL096973NHLBI NIH HHS R01HL096973NHLBI NIH HHS R01 HL098032NHLBI NIH HHS R01HL098032NIDDK NIH HHS RC1 DK085852NIDDK NIH HHS RC1DK085852NIGMS NIH HHS R01 GM057384NIGMS NIH HHS R01GM57384
6 · The paper itself

Abstract

Vascular disease, a significant cause of morbidity and mortality in the developed world, results from vascular injury. Following vascular injury, damaged or dysfunctional endothelial cells and activated SMCs engage in vasoproliferative remodeling and the formation of flow-limiting intimal hyperplasia (IH). We hypothesized that vascular injury results in decreased bioavailability of NO secondary to dysregulated arginine-dependent NO generation. Furthermore, we postulated that nitrite-dependent NO generation is augmented as an adaptive response to limit vascular injury/proliferation and can be harnessed for its protective effects. Here we report that sodium nitrite (intraperitoneal, inhaled, or oral) limited the development of IH in a rat model of vascular injury. Additionally, nitrite led to the generation of NO in vessels and SMCs, as well as limited SMC proliferation via p21Waf1/Cip1 signaling. These data demonstrate that IH is associated with increased arginase-1 levels, which leads to decreased NO production and bioavailability. Vascular injury also was associated with increased levels of xanthine oxidoreductase (XOR), a known nitrite reductase. Chronic inhibition of XOR and a diet deficient in nitrate/nitrite each exacerbated vascular injury. Moreover, established IH was reversed by dietary supplementation of nitrite. The vasoprotective effects of nitrite were counteracted by inhibition of XOR. These data illustrate the importance of nitrite-generated NO as an endogenous adaptive response and as a pathway that can be harnessed for therapeutic benefit.

Indexed as

AnimalsArginaseArginineCell ProliferationCyclin-Dependent Kinase Inhibitor p21HyperplasiaMaleMyocytes, Smooth MuscleNitric OxideNitric Oxide Synthase Type IIIRatsRats, Sprague-DawleySignal TransductionSodium NitriteTunica IntimaXanthine DehydrogenaseArginasearginase I, ratArginineCdkn1a protein, ratCyclin-Dependent Kinase Inhibitor p21Nitric OxideNitric Oxide Synthase Type IIINos3 protein, ratSodium NitriteXanthine Dehydrogenase

Identifiers

PMID21436585
PMCPMC3069768
OpenAlexW2082664405

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.